chronic neutrophilic leukemia | Page 2

W S Zheng, L X Guan, L C Cheng, Y L Hu, Y Y Xu, T Yang, B Peng, Y L Wu, J Bo, Q S Wang, X N Gao
No abstract text is available yet for this article.
February 23, 2020: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Fanqi Jin, Fengshan Wang
In the past decades, the roles of carbohydrates in living organisms and their potential use in many fields have been extensively investigated. Sialyl Lewis x (sLex ), a member of body carbohydrate, is an inherent blood-type tetrasaccharide on the surface of different cells, the lymphocyte, neutrophil, some T cells, multiple tumor cells and so on. SLex is a common ligand of the three selectins, L-selectin, E-selectin and P-selectin, and plays important roles in multiple physiological phenomenas by interacting with selectins...
February 15, 2020: Glycoconjugate Journal
Luciana Teofili, Patrizia Chiusolo, Caterina Giovanna Valentini, Elisabetta Metafuni, Silvia Bellesi, Nicoletta Orlando, Maria Bianchi, Sabrina Giammarco, Simona Sica, Andrea Bacigalupo
We analyzed data relative to cell content in 88 consecutive patients receiving HLA haploidentical bone marrow (BM) transplants with post-transplantation cyclophosphamide (PT-CY). Median age was 54.5 (range, 17-72); diagnoses were acute leukemia (n = 46), lymphoproliferative disorders (n = 24), myelofibrosis (n = 11) and myelodysplastic syndromes (n = 5). Total nucleated cell (TNC) and CD34+, CD3+, CD4+ and CD8+ cell doses were stratified as higher than first, second and third quartile and the dose effect on various clinical outcomes was assessed...
March 2020: Cytotherapy
Amandeep Salhotra, Dongyun Yang, Sally Mokhtari, Monzr M Al Malki, Haris Ali, Karamjeet S Sandhu, Ahmed Aribi, Samer Khaled, Matthew Mei, Elizabeth Budde, David Snyder, Thai Cao, Ricardo Spielberger, Guido Marcucci, Vinod Pullarkat, Stephen J Forman, Ryotaro Nakamura, Anthony Stein, Ibrahim Aldoss
Historically, outcomes of adult patients with relapsed acute lymphoblastic leukemia (ALL) who fail to enter remission with conventional chemotherapy are very poor. Blinatumomab, a bispecific CD3/CD19 antibody, has shown remarkable activity in relapsed/refractory (r/r) ALL. Although allogeneic hematopoietic cell transplant (HCT) is the recommended consolidation therapy for patients with r/r ALL who respond to salvage therapy, HCT and toxicity outcomes for those who received blinatumomab salvage and HCT remain largely unknown...
June 2020: Biology of Blood and Marrow Transplantation
Yu-Jie Guo, Yan Wang, Li-Hua Wang, Ya-Bei Zuo, Zhi-Yun Niu, Feng-Ru Lin, Jing-Yu Zhang
OBJECTIVE: To provide clinical basis for the diagnosis and treatment of chronic neutrophilic leukemia (CNL) and to provide possible molecular targets for the treatment. METHODS: By summarizing the clinical data of 14 patients with CNL, the clinical characteristics, gene mutation types and possible prognostic factors were analyzed. RESULTS: Among the 14 patients with CNL, males (9 cases) were more than females (5 cases), with a median age of 57 years old...
February 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
M He, X C Zhao, H Bai
No abstract text is available yet for this article.
December 14, 2019: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Ibrahim Alatawneh, Alex Zvulunov
Neutrophilic dermatosis of the hands (NDH) is a rare localized variant of Sweet's syndrome occurring predominantly over dorsa of hands. Both Sweet's syndrome and its dorsal hand variant have been reported in association with malignancies, inflammatory bowel diseases, and drugs. We report a patient with neutrophilic dermatoses of dorsal hands associated with chronic lymphocytic leukemia (CLL).
January 2020: Harefuah
Jacey Guthrie, Caleb King, Laura Battle, Halle Field, Pooja Motwani, Henry Wong, Jennifer Kaley, Mallory Shiver, Ling Gao
Diagnosis of a neutrophilic dermatosis, such as pyoderma gangrenosum (PG), often is challenging at onset because it can be impossible to distinguish clinically and histopathologically from an acute infection in an immunosuppressed patient, necessitating a detailed patient history as well as correlation pathology with microbial tissue cultures. The dermatologist's ability to distinguish a neutrophilic dermatosis from active infection is of paramount importance, as the decision to treat with surgical debridement, in addition to an antibiotic regimen, can have grave consequences in the misdiagnosed patient...
November 2019: Cutis; Cutaneous Medicine for the Practitioner
Kim-Hien T Dao, Jason Gotlib, Michael M N Deininger, Stephen T Oh, Jorge E Cortes, Robert H Collins, Elliot F Winton, Dana R Parker, Hyunjung Lee, Anna Reister, Schultz, Samantha Savage, Stevens, Chase Brockett, Nan Subbiah, Richard D Press, Philipp W Raess, Michael Cascio, Jennifer Dunlap, Yiyi Chen, Catherine Degnin, Julia E Maxson, Cristina E Tognon, Tara Macey, Brian J Druker, Jeffrey W Tyner
PURPOSE: Colony-stimulating factor-3 receptor ( CSF3R )-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS: We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML)...
April 1, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Hirohiko Shibayama, Takanori Teshima, Ilseung Choi, Kiyohiko Hatake, Naohiro Sekiguchi, Nozomi Yoshinari
This phase I study evaluated the safety and efficacy of single-agent ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (aged 20-69 years and ineligible for chemotherapy using fludarabine or cyclophosphamide, or aged ≥70 years). Eight patients received oral ibrutinib 420 mg once daily until progressive disease or unacceptable toxicity. The primary endpoint was safety; secondary endpoints included the overall response rate (ORR). At the time of final analysis (August 22, 2018), eight patients (all with CLL; median age, 68...
2019: Journal of Clinical and Experimental Hematopathology: JCEH
Andrea Price, Lawrence J Druhan, Amanda Lance, Gavin Clark, C Greer Vestal, Qing Zhang, David Foureau, Judy Parsons, Alicia Hamilton, Nury M Steuerwald, Belinda R Avalos
Activating mutations in the membrane-proximal region of the colony-stimulating factor 3 receptor (CSF3R) are a hallmark of chronic neutrophilic leukemia (CNL) with the T618I mutation being most common. The mechanisms underlying constitutive activation of the T618I CSF3R and its signal propagation are poorly understood. Ligand-independent activation of the T618I CSF3R has previously been attributed to loss of receptor O-glycosylation and increased receptor dimerization. Here, we show that the T618I CSF3R is indeed glycosylated but undergoes enhanced spontaneous internalization and degradation that results in a marked decrease in its surface expression...
February 26, 2020: Biochemical and Biophysical Research Communications
Yoshio Okamoto, Sumie Tabata, Sho Shibata, Yoko Takiuchi, Kazuyo Yamamoto, Akiko Aiba, Toshiyuki Kitano, Nobuyoshi Arima
A 61-year-old man was admitted to our hospital with fever and massive leukocytosis. A bone marrow smear revealed an increased density of myeloid cells in various stages of maturation as well as dysplasia in the neutrophils. There was no proliferation of blasts, eosinophils, or basophils. Genomic analysis of the bone marrow cells revealed no detectable abnormalities associated with myeloproliferative neoplasms, including BCR-ABL1. Therefore, the patient was diagnosed with atypical chronic myeloid leukemia (aCML)...
2019: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
H Ai, Y W Fu, Y Q Wang, X D Wei, Y P Song
Objective: To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) containing cladribine sequential busulfan regimen for refractory/relapsed acute myeloid leukemia (AML) . Methods: The clinical data of 12 refractory/relapsed AML patients received allo-HSCT with cladribine sequential busulfan regimen. Results: ① Of the 12 patients, 9 were males and 3 females, with a median age of 36 (27-50) years. The donors were identical sibling (3) , matched unrelated (1) and haploidentical family member (9) respectively...
October 14, 2019: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Natasha Szuber, Michelle Elliott, Ayalew Tefferi
DISEASE OVERVIEW: Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL in 2013 anchored a new scientific framework, deepening our understanding of its molecular pathogenesis, providing a diagnostic biomarker, and rationalizing the use of pharmacological targeting...
February 2020: American Journal of Hematology
Nicolas Duployez, Christophe Willekens, Isabelle Plo, Alice Marceau-Renaut, Stéphane de Botton, Laurène Fenwarth, Thomas Boyer, Guillemette Huet, Olivier Nibourel, Christian Rose, Brigitte Nelken, Bruno Quesnel, Claude Preudhomme
No abstract text is available yet for this article.
December 26, 2019: Blood
Ami B Patel, Anca Franzini, Emilie Leroy, Soo Jin Kim, Anthony D Pomicter, Lidvine Genet, Michael Xiao, Dongqing Yan, Jonathan Ahmann, Archana M Agarwal, Phillip Clair, Juanah Addada, Jonathan Lambert, Matthew Salmon, Gerald J Gleich, Nicholas Cp Cross, Stefan Constantinescu, Thomas O'Hare, Josef T Prchal, Michael W Deininger
The V617F mutation in the JH2 domain of JAK2 is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV). Other mutations in JAK2 have been identified in MPNs, most notably exon 12 mutations in PV. Here, we describe a novel recurrent mutation characterized by a common 4-amino acid deletion and variable 1-amino acid insertion (Leu583-Ala586DelInsSer/Gln/Pro) within the JH2 domain of JAK2. All four affected patients had eosinophilia, and both patients with Leu583-Ala586DelInsSer fulfilled diagnostic criteria of both PV and chronic eosinophilic leukemia (CEL)...
October 11, 2019: Blood
Danielle Cuthbert, Brady Lee Stein
Polycythemia vera is a Philadelphia-negative chronic myeloproliferative neoplasm, characterized by erythrocytosis, which is unique, compared to essential thrombocytosis and primary myelofibrosis. Though longevity can usually be expected, vascular morbidity is associated with this condition, as well as a propensity to evolve into myelofibrosis (post-PV MF) and acute myeloid leukemia. In addition, patients can have a pronounced symptom burden. Herein, contributors to the symptomatic burden, as well as the thrombotic and transformative tendencies are reviewed...
2019: Journal of Blood Medicine
Jae Won Yun, Jung Yoon, Chul Won Jung, Ki-O Lee, Jong Won Kim, Sun-Hee Kim, Hee-Jin Kim
BACKGROUND: Atypical chronic myeloid leukemia (aCML) is a hematologic disorder characterized by leukocytosis with increased dysplastic neutrophils and their precursors. In CSF3R gene, the activation mutation including T618I is frequently reported in aCML but is rarely accompanied by truncation mutations. Herein, we report a unique aCML patient with two CSF3R mutations (T618I and Y779*) in the same DNA strand. METHODS: High-coverage next-generation sequencing for 40 genes related with myeloid leukemia was performed...
November 6, 2019: Journal of Clinical Laboratory Analysis
Yu-Lin Su, Marcin Kortylewski
Neutrophils are early wound healing and inflammation regulators that, due to functional plasticity, can adopt either pro- or antitumor functions. Until recently, beclin-1 was a protein known mainly for its role as a critical regulator of autophagy. In this issue of the JCI, Tan et al. describe the effects of the beclin-1 conditional myeloid cell-specific deletion in mice, in which immunostimulation resulted in hypersensitive neutrophils. The chronic proinflammatory effect of these neutrophils triggered spontaneous B cell malignancies to develop...
October 28, 2019: Journal of Clinical Investigation
Ka-Young Ryu, Hyun-Ju Lee, Hanwoong Woo, Ri-Jin Kang, Kyung-Min Han, HyunHee Park, Sang Min Lee, Ju-Young Lee, Yoo Joo Jeong, Hyun-Wook Nam, Youngpyo Nam, Hyang-Sook Hoe
BACKGROUND: The FDA-approved small-molecule drug dasatinib is currently used as a treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on microglial and/or astrocytic neuroinflammatory responses and its mechanism of action have not been studied in detail. METHODS: BV2 microglial cells, primary astrocytes, or primary microglial cells were treated with dasatinib (100 or 250 nM) or vehicle (1% DMSO) for 30 min or 2 h followed by lipopolysaccharide (LPS; 200 ng/ml or 1 μg/ml) or PBS for 5...
October 26, 2019: Journal of Neuroinflammation
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"